Background illustration for clinical trials search

Paid Clinical Trials Wichita

Discover 130 paid clinical trials in Wichita, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 130

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

for

Hypertension (HTN)

Location: Wichita KS, Edmond OK, Jefferson City MO, Memphis TN,

Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07543120

Phase2, Recruiting

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

for

Migraine

Location: Wichita KS, Edmond OK, Tulsa OK, Oklahoma City OK,

Sponsor: Kallyope Inc.

Sex: All

Age: 18 - 70+

Code: NCT07645924

Phase3, Recruiting

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

for

Acute Migraine

Location: Wichita KS, Edmond OK, Tulsa OK, Oklahoma City OK,

Sponsor: Kallyope Inc.

Sex: All

Age: 18+

Code: NCT07674654

Phase3, Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

for

Heart Failure and Impaired Kidney Function

Location: Wichita KS, Kansas City MO, Lincoln NE, Columbia MO,

Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT06307652

Phase3, Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

for

Chronic Kidney Disease and Hypertension

Location: Wichita KS, Hutchinson KS, Kansas City KS,

Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06742723

Phase3, Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

for

COPD (Chronic Obstructive Pulmonary Disease)

Location: Wichita KS, Tulsa OK, Oklahoma City OK, Norman OK,

Sponsor: AstraZeneca

Sex: All

Age: 40 - 70+

Code: NCT06283966

Phase3, Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

for

Atrial Fibrillation (AF)

Location: Wichita KS, Hutchinson KS, Oklahoma City OK,

Sponsor: Anthos Therapeutics, Inc.

Sex: All

Age: 65+

Code: NCT05712200

Phase3, Recruiting

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

for

Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma,

Location: Wichita KS, Oklahoma City OK, Kansas City KS,

Sponsor: Sameek Roychowdhury

Sex: All

Age: 18+

Code: NCT06906562

Phase2, Recruiting

IC-8 Apthera IOL New Enrollment Post Approval Study

for

Cataract, Presbyopia, Posterior Capsule Opacification

Location: Wichita KS, Omaha NE, Rock Island IL, Sugar Land TX,

Sponsor: Bausch & Lomb Incorporated

Sex: All

Age: 22+

Code: NCT06060041

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

for

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Location: Wichita KS, Dallas TX, Little Rock AR, Denver CO,

Sponsor: Ferring Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06545955

Phase3, Recruiting

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

for

Prostate Cancer,

Location: Wichita KS, Dallas TX, Albuquerque NM, Houston TX,

Sponsor: Astellas Pharma Global Development, Inc.

Sex: Male

Age: 18+

Code: NCT04729114

Phase1, Recruiting

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

for

High-Risk Non-Muscle-Invasive Bladder Cancer

Location: Wichita KS, Omaha NE, Clive IA, Dallas TX,

Sponsor: CG Oncology, Inc.

Sex: All

Age: 18+

Code: NCT06567743

Phase2, Recruiting

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

for

Prostate Cancer, Prostatic Neoplasms

Location: Wichita KS, Tulsa OK, Omaha NE, Dallas TX,

Sponsor: Clarity Pharmaceuticals Ltd

Sex: Male

Age: 18+

Code: NCT06056830

Phase3, Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

for

Non-Muscle Invasive Bladder Cancer

Location: Wichita KS, Omaha NE, Dallas TX, St Louis MO, Aurora CO,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06319820

Phase3, Recruiting

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

for

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Location: Wichita KS, Omaha NE, Clive IA, Dallas TX,

Sponsor: Ferring Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06510374

Phase3, Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

for

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Location: Wichita KS, Westwood KS, Iowa City IA, Birmingham AL,

Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07190300

Phase1, Phase2, Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

for

Progressive Metastatic Castrate Resistant Prostate Cancer

Location: Wichita KS, Denver CO, Jacksonville FL, Atlanta GA,

Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07206056

Phase1, Phase2, Recruiting

Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial

for

Kidney Calculi; Ureteral Calculi

Location: Wichita KS, Woodbury MN, San Antonio TX,

Sponsor: Avvio Medical

Sex: All

Age: 21+

Code: NCT06942949

Recruiting

Prospective US Radiofrequency SUI Trial

for

Urinary Incontinence, Stress

Location: Wichita KS, Irving TX, Shreveport LA, Maplewood MN,

Sponsor: Viveve Inc.

Sex: Female

Age: 18+

Code: NCT04720352

Recruiting

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

for

Overactive Bladder, Urge Incontinence, Incontinence, Urinary,

Location: Wichita KS, Kansas City KS, Ankeny IA, Little Rock AR,

Sponsor: Valencia Technologies Corporation

Sex: All

Age: 18+

Code: NCT05685433

Recruiting

Paid Clinical Trials Wichita

Filter results

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Interested in new trials?

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

IC-8 Apthera IOL New Enrollment Post Approval Study

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial

Prospective US Radiofrequency SUI Trial

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)